SBIR Top Score

(Chicago, Illinois) — March 20, 2025

ExoMira Medicine is proud to announce that Chief Scientific Officer Dr. Andrew Hoffmann has received an outstanding fundable score on the company’s SBIR (Small Business Innovation Research) grant application focused on the development of its USP22 inhibitor program. This highly competitive federal funding mechanism is designed to support breakthrough innovations with strong commercial potential, and receiving a top-tier score reflects strong enthusiasm and validation from expert reviewers for ExoMira’s science and therapeutic strategy.

These early-stage SBIR grants not only provide critical non-dilutive funding to advance preclinical studies, but also serve as a pathway to significantly larger Phase II and Phase IIB follow-on awards, which can support IND-enabling studies and early-stage clinical trials. This validation represents a major milestone in ExoMira’s pursuit of novel pancancer immunotherapies targeting USP22.